排序方式: 共有76条查询结果,搜索用时 46 毫秒
1.
Biswas Mainak Saba Luca Omerzu Tomaž Johri Amer M. Khanna Narendra N. Viskovic Klaudija Mavrogeni Sophie Laird John R. Pareek Gyan Miner Martin Balestrieri Antonella Sfikakis Petros P Protogerou Athanasios Misra Durga Prasanna Agarwal Vikas Kitas George D Kolluri Raghu Sharma Aditya Viswanathan Vijay Ruzsa Zoltan Nicolaides Andrew Suri Jasjit S. 《Journal of digital imaging》2021,34(3):581-604
Journal of Digital Imaging - Cardiovascular diseases (CVDs) are the top ten leading causes of death worldwide. Atherosclerosis disease in the arteries is the main cause of the CVD, leading to... 相似文献
2.
3.
4.
5.
Sophie Mavrogeni George Markousis-Mavrogenis Antigoni Papavasiliou Genovefa Kolovou 《World journal of cardiology》2015,7(7):410-414
Duchenne and Becker muscular dystrophy (DMD/BMD) are X-linked muscular diseases responsible for over 80% of all muscular dystrophies. Cardiac disease is a common manifestation, not necessarily related to the degree of skeletal myopathy; it may be the predominant manifestation with or without any other evidence of muscular disease. Death is usually due to ventricular dysfunction, heart block or malignant arrhythmias. Not only DMD/BMD patients, but also female carriers may present cardiac involvement. Clinically overt heart failure in dystrophinopathies may be delayed or absent, due to relative physical inactivity. The commonest electrocardiographic findings include conduction defects, arrhythmias (supraventricular or ventricular), hypertrophy and evidence of myocardial necrosis. Echocardiography can assess a marked variability of left ventricular dysfunction, independently of age of onset or mutation groups. Cardiovascular magnetic resonance (CMR) has documented a pattern of epicardial fibrosis in both dystrophinopathies’ patients and carriers that can be observed even if overt muscular disease is absent. Recently, new CMR techniques, such as postcontrast myocardial T1 mapping, have been used in Duchenne muscular dystrophy to detect diffuse myocardial fibrosis. A combined approach using clinical assessment and CMR evaluation may motivate early cardioprotective treatment in both patients and asymptomatic carriers and delay the development of serious cardiac complications. 相似文献
6.
Sophie Mavrogeni Antigoni Papavasiliou Marouso Douskou Genovefa Kolovou Evangelia Papadopoulou Dennis V. Cokkinos 《European journal of paediatric neurology》2009,13(1):34-40
ObjectiveTo evaluate the involvement of cardiac and sternocleidomastoid muscles by magnetic resonance imaging (MRI) measurement of T2 relaxation time and the left ventricular systolic function in patients with Duchenne muscular dystrophy (DMD) on treatment with deflazacort and compare them with DMD patients without treatment.SubjectsSeventeen patients with DMD (aged 17–22 years) on treatment with deflazacort for at least 7 years and 17 boys with DMD of younger age (12–15 years) without steroid treatment. All patients were free of cardiac or respiratory symptoms and had normal ECG and Holter monitor examination.MethodsT2 relaxation time of the myocardium (H), left (SCM-L) and right sternocleidomastoid (SCM-R) muscles and left ventricular systolic function were evaluated by magnetic resonance imaging (MRI) in two groups of DMD patients. Myocardial and sternocleidomastoid muscles T2 relaxation time was calculated using 16 TEs (10–85 msec) and TR at least 2000 ms and T2 maps were created.ResultsDMD on deflazacort had higher T2 relaxation time values of the heart and of both sternocleidomastoid muscles (T2H median (range): 47 (41–48) vs. 33 (31–37) ms, p<0.001, T2 SCM-L median (range): 35 (30–37) vs. 23 (20–26) ms, p<0.001, T2 SCM-R median (range): 35 (32–37) vs. 23 (20–27) ms, p<0.001) and left ventricular systolic function (LVEDV median (range): 95 (75–120) vs. 90 (80–105) ml, p=0.03, LVESV median (range): 45 (38–55) vs. 47 (41–51) ml, p=0.81(NS), LVEF median (range): 53% (51–57) vs. 48% (42–51), p<0.001) compared to DMD without treatment.ConclusionsDMD patients on deflazacort are characterized by better preservation of the T2 relaxation time of myocardium and sternocleidomastoid muscles and better LV systolic function. The duration of this beneficial effect needs to be studied prospectively. 相似文献
7.
Mavrogeni S Gotsis ED Berdousi E Ladis V Verganelakis D Toulas P Cokkinos DV 《The international journal of cardiovascular imaging》2007,23(6):739-745
Bone marrow transplantation (BMT) is the only complete cure for b-thalassemia. Iron depletion therapy is still required to
remove excess iron, accumulated before BMT. Hepatic and myocardial iron load were evaluated using T2* magnetic resonance in
8 ex-thalassemic patients after BMT, aged 19.5 ± 4.25 years, who were in iron depletion therapy. Average hepatic T2* was 18.8 ± 11.0 msec
(4.1–35.0 msec). In 4 out of 8 patients iron overload was detected, not exceeding however 4 mg/gr dry tissue. Average heart
T2* was 31.0 ± 4.6 msec (25.6–35.2 msec), not significantly different (P = 0.18) from our age-matched normal population (33.0 ± 4.0). Normal left ventricular ejection fraction was found in 7 out
of 8 patients (mean 64.5 ± 7.0%) with the remaining having a marginal value of 54.1%. Ferritin level before BMT was 1748 ± 451 μg/l
and dropped to 536 ± 260 μg/l at the end of iron depletion therapy after BMT. Current ferritin level was 271 ± 253 μg/l and
although it was significant lower compared to both ferritin before BMT (P < 0.001) and after iron depletion (P < 0.001), evidence of residual hepatic iron load was identified by T2*. Hepatic and myocardial T2* magnetic resonance can
be used as a more reliable index than ferritin for evaluation of iron depletion therapy in ex-thalassemic patients after BMT. 相似文献
8.
Mavrogeni S Giamouzis G Papadopoulou E Thomopoulou S Dritsas A Athanasopoulos G Adreanides E Vassiliadis I Spargias K Panagiotakos D Cokkinos DV 《Journal of cardiac failure》2007,13(7):556-559
BackgroundLevosimendan (LS) improves cardiac contractility without increasing myocardial oxygen demand. We administrated LS on a monthly intermittent 24-hour protocol and evaluated the clinical effect after 6 months in a randomized, open, prospective study.Methods and ResultsFifty patients (age 45–65 years) with LV systolic dysfunction and New York Heart Association (NYHA) III or IV were randomized in 2 groups. LS group (n = 25) was compared with a control group (n = 25) matched for sex, age, and NYHA class. LS was given monthly on a 24-hour intravenous protocol for 6 months. Patients were evaluated by specific activity questionnaire (SAQ) and echocardiography (ECHO) before and 3 to 5 days after last drug administration, whereas 24-hour Holter recording was performed before and during last drug administration. Patients in LS and control group had same baseline SAQ, ECHO, and Holter parameters. At the end of the study, a larger proportion of patients in the levosimendan group reported improvement in symptoms (dyspnea and fatigue) (65% versus 20% in controls, P < .01). After 6 months, the LS group had a significant increase in LV ejection fraction versus controls (28 ± 7 versus 21 ± 4 %, P = .003), LV shortening fraction (15 ± 3 versus 11 ± 3 %, P = .006) and a decrease in mitral regurgitation (1.5 ± 0.8 versus 2.7 ± 0.6, P = .0001). There was no increase in supraventricular or ventricular beats or supraventricular tachycardia and VT episodes in LS group, compared with controls. Two patients from the LS group died in the 6-month follow-up period, compared with 8 patients in the control group (8% versus 32%, P < .05).ConclusionsA 6-month intermittent LS treatment in patients with decompensated advanced heart failure improved symptoms and LV systolic function. 相似文献
9.
Giorgos L. Chouliaras Antonis Kattamis Vasilis Berdoukas Efstathios D. Gotsis Sophie Mavrogeni Vassilis Ladis 《British journal of haematology》2010,151(4):397-401
Cardiac Magnetic Resonance (CMR) has replaced all other surrogate measurements in the determination of transfusional cardiac iron overload in patients with thalassaemia major. We aimed to determine the diagnostic value of CMR T2* with respect to cardiac dysfunction (CD) as determined by CMR‐derived left ventricular ejection fraction (LVEF). Cardiac T2* values and LVEF measured by CMR were recorded in 303 patients with thalassaemia major, at the time of their first CMR. T2* was correlated with LVEF (regression coefficient: 0·57, P < 0·001). The prevalence of CD was 32·9% in patients with T2* ≤ 8 ms, 12·5% in patients with T2* > 8 ms and ≤14 ms and reduced to 9·1% in patients with T2* between 14–20 ms. As the probability of CD is progressively, and not suddenly, reduced with increasing values of T2*, CMR has a limited diagnostic value for CD (Receiver operating characteristic analysis, area under the curve = 0·68). Patients with cardiac T2* ≤ 8 ms require careful and intensive management. This risk decreases with increasing values of T2* but even in mildly loaded patients the probability of impaired LVEF is not negligible. 相似文献
10.